ADMdx provides FDA‑cleared software, CorInsights® MRI, that extracts quantitative volumetric data from standard brain MRI scans to enable earlier, more accurate diagnosis of Alzheimer’s disease, other dementias, Parkinson’s disease, and traumatic brain injury. The company also offers a full suite of CNS imaging CRO services—including AI‑driven pattern analysis, centralized data management, and radiology read platforms—to help radiology practices, academic centers, and pharma/biotech sponsors standardize imaging biomarkers and improve clinical trial efficiency.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Accurate diagnosis and monitoring of brain disorders such as Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury rely on complex imaging biomarkers that are difficult to quantify, require specialized expertise, and lack standardized, regulatory‑cleared tools. This hampers early detection, patient stratification, and the ability of clinical trials to reliably measure treatment effects.
Solution
ADMdx addresses these gaps by applying advanced image measurement, AI‑driven pattern analysis, and regulatory‑cleared software to standard MRI and PET scans. Their CorInsights® MRI product delivers quantitative brain‑tissue volume reports that are FDA 510(k) cleared, enabling radiologists and neurologists to incorporate objective metrics into routine care. For pharmaceutical and academic sponsors, ADMdx offers a full suite of CNS imaging CRO services—including protocol development, site qualification, centralized data management, radiology reads via CIReader™, and multivariate image analysis—to improve trial efficiency and statistical power. A patented machine‑learning method can disentangle overlapping disease signatures within a single scan, supporting both diagnostic differentiation and enrichment/stratification in drug development programs.
Target Audience
Primary customers are radiology and neurology practices, academic medical centers, and pharmaceutical/biotech companies conducting CNS clinical trials that require standardized, quantitative imaging biomarkers and expert CRO support.
Features
- FDA 510(k) cleared CorInsights® MRI software that extracts quantitative volumetric data from standard brain MRI scans
- CIReader™ platform for secure, guided radiology reads with customizable electronic case report forms and image annotation
- CITrials™ data‑management system providing encrypted upload, de‑identification, site tracking, and automated quality checks
- Multimodal imaging support (volumetric MRI, DTI/DSI, fMRI, ASL, Tau PET, Amyloid PET, FDG PET, and other tracers)
- Machine‑learning based pattern analysis patented to separate co‑existing disease effects within a single brain scan
- End‑to‑end CRO capabilities: protocol design, site qualification, centralized QC, advanced image processing, disease classification, trajectory prediction, and regulatory‑compliant reporting
- Integration of imaging biomarkers with plasma biomarker data to enhance diagnostic insight and trial endpoint correlation